Interleukin 12-Engineered Cell Vaccine Demonstrates 80% Efficacy in Preventing Breast Cancer

Strategic Insights -

Researchers have developed an interleukin 12-engineered allogeneic cell vaccine that exhibits a remarkable 80% efficacy in preventing HER-2/neu transgenic breast cancer in mice. This breakthrough study, published in the journal Cancer Research, highlights the potential of immunotherapy in cancer prevention. The vaccine, engineered to release interleukin (IL)-12, has shown to induce a strong anti-HER-2/neu antibody response and a high production of IFN-gamma and IL-4, which are crucial for immune protection.

Key Takeaways:

  • The interleukin 12-engineered allogeneic cell vaccine prevented tumor development in 80% of 1-year-old BALB-neuT mice.
  • The vaccine showed the most powerful immunopreventive activity compared to other cytokine-engineered cells.
  • Whole mount, histology, immunohistochemistry, and gene expression profile analysis revealed that vaccination with IL-12-engineered cells maintained 26-week mammary glands free of neoplastic growth.
  • The IL-12-engineered cell vaccine elicited a high production of IFN-gamma, IL-4, and a strong anti-HER-2/neu antibody response.
  • Immune protection was lost or markedly impaired in BALB-neuT mice lacking IFN-gamma or antibody production.
  • The vaccine induced much lower circulating IL-12 and IFN-gamma, resulting in lower potential side effects and systemic toxicity.
  • Researchers from the University of Bologna and collaborators in Italy conducted the study under the guidance of Carla de Giovanni.

Statistics:

  • 80% of 1-year-old BALB-neuT mice were free of tumors after receiving the IL-12-engineered cell vaccine.
  • The vaccine prevented tumor development compared to 0% of untreated mice and mice vaccinated with IL-12-engineered cells lacking either HER-2/neu or allogeneic antigens.
  • The gene expression profile analysis showed that vaccination with IL-12-engineered cells clustered with that of untreated preneoplastic glands.

Sources:

  • de Giovanni, C., et al. (2004). Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res, 64(11), 4001-4009.
  • American Association for Cancer Research. (Publisher).